Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Oncology

Background:

• Chronic progressive multiple sclerosis (MS) is a debilitating neurological disease.
• Current treatments for MS have limitations in efficacy and side effect profiles.
• Investigating novel therapeutic agents is crucial for managing MS progression.

Purpose of the Study:

• To evaluate the efficacy and safety of intensive cyclophosphamide therapy in patients with chronic progressive multiple sclerosis.
• To assess the neurological status and disease progression following cyclophosphamide treatment.
• To determine the feasibility of continuing cyclophosphamide therapy given its side effect profile and oncogenic potential.

Main Methods:

• A preliminary uncontrolled trial involving 14 patients with chronic progressive MS.
• Short course of intensive cyclophosphamide therapy administered.
• Treatment discontinued if leukocyte count dropped to 3000 cells/mm³.
• Neurological assessments conducted at 1 and 2-year follow-ups.

Main Results:

• Five out of 14 patients discontinued treatment due to severe side effects.
• No significant neurological improvement was observed in patients at 1-year follow-up.
• Four patients remained neurologically stable at the 2-year follow-up.
• The therapy was discontinued due to lack of clinical benefit and significant adverse events.

Conclusions:

• Intensive cyclophosphamide therapy demonstrated a lack of clinical efficacy in chronic progressive multiple sclerosis.
• The high incidence of severe side effects and the known oncogenicity of cyclophosphamide outweigh potential benefits.
• Further investigation into cyclophosphamide for MS is not recommended based on these findings.